Your AI-Trained Oncology Knowledge Connection!

Myelodysplastic Syndromes (MDS): Recent Updates and Evolving Treatment Paradigms : Episode 2

Video

June 26, 2023

Risk Stratification of MDS

Author(s):

Amer Zeidan, MBBS, MHS, explains risk stratification in MDS, how the process has evolved over time, and the guidelines he typically follows.

EP: 1.Diagnosing Myelodysplastic Syndromes (MDS)

Now Viewing

EP: 2.Risk Stratification of MDS

EP: 3.First-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

EP: 4.Initiating Treatment for Lower-Risk MDS With Symptomatic Anemia

EP: 5.Monitoring Treatment With ESAs for Lower-Risk MDS With Symptomatic Anemia

EP: 6.Second-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

EP: 7.Patient Profile: A 75-Year-Old Man With Lower-Risk MDS and Symptomatic Anemia

EP: 8.Treatment Approaches for Lower-Risk MDS With Symptomatic Anemia

EP: 9.Patient Profile: A 79-Year-Old Man With Lower-Risk MDS and a KRAS Mutation

EP: 10.Treatment Approaches for Lower-Risk MDS With RAS Mutations

EP: 11.ESA Outcomes by SF3B1 Mutation Status in Lower-Risk MDS

EP: 12.Luspatercept for Lower-Risk MDS: Data From the COMMANDS Trial

EP: 13.Imetelstat for Lower-Risk MDS: Data From the IMerge Trial

EP: 14.Oral HMAs in Lower-Risk MDS Treatment

EP: 15.IRAK1 and IRAK4 Inhibitors for the Treatment of Lower-Risk MDS

EP: 16.Key Trials in the Treatment of Higher-Risk MDS

EP: 17.Final Thoughts on Recent Data Updates in MDS

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All

Video

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

May 9th 2025 - Jun 14th 2025

online-activity

Video

Proactive Adverse Event Management for HER2+ BTC Treatments

May 8th 2025 - May 9th 2026

online-activity

Video

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

May 2nd 2025 - Jun 7th 2025

online-activity

Latest Conference Coverage

Breast Cancer Experts Bookmark Top Abstracts to Watch at the 2025 ASCO Annual Meeting

Poll Results Punctuate Key Lung Cancer Abstracts Driving Intrigue Ahead of ASCO 2025

Insights From Liso-cel Combined With Ibr for R/RCLL/SLL: Primary Results From the Open-Label, Phase 1/2 Transcend CLL 004 Study

Overview of the Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients With Previously Untreated DLBCL Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

Risk Stratification of MDS

EP: 1.Diagnosing Myelodysplastic Syndromes (MDS)

EP: 2.Risk Stratification of MDS

EP: 3.First-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

EP: 4.Initiating Treatment for Lower-Risk MDS With Symptomatic Anemia

EP: 5.Monitoring Treatment With ESAs for Lower-Risk MDS With Symptomatic Anemia

EP: 6.Second-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia

EP: 7.Patient Profile: A 75-Year-Old Man With Lower-Risk MDS and Symptomatic Anemia

EP: 8.Treatment Approaches for Lower-Risk MDS With Symptomatic Anemia

EP: 9.Patient Profile: A 79-Year-Old Man With Lower-Risk MDS and a KRAS Mutation

EP: 10.Treatment Approaches for Lower-Risk MDS With RAS Mutations

EP: 11.ESA Outcomes by SF3B1 Mutation Status in Lower-Risk MDS

EP: 12.Luspatercept for Lower-Risk MDS: Data From the COMMANDS Trial

EP: 13.Imetelstat for Lower-Risk MDS: Data From the IMerge Trial

EP: 14.Oral HMAs in Lower-Risk MDS Treatment

EP: 15.IRAK1 and IRAK4 Inhibitors for the Treatment of Lower-Risk MDS

EP: 16.Key Trials in the Treatment of Higher-Risk MDS

EP: 17.Final Thoughts on Recent Data Updates in MDS

Newsletter

Latest CME

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments | Kansas

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

Proactive Adverse Event Management for HER2+ BTC Treatments

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments | Kansas

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

Proactive Adverse Event Management for HER2+ BTC Treatments

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments | Kansas

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Latest Conference Coverage